Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
{{output}}
Background: Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials. We report result... ...
